OZURDEX™
(dexamethasone intravitreal implant)

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use OZURDEX™ safely and effectively. See full prescribing information.

OZURDEX™ contains a corticosteroid indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). (1)

DOSAGE AND ADMINISTRATION (2.1)

• For ophthalmic intravitreal injection only. (2.1)

The intravitreal injection procedure should be carried out under controlled aseptic conditions. Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. (2.2)

Dosage Forms and Strengths
• Intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR™ solid polymer drug delivery system. (3)

CONTRAINDICATIONS
• Ocular or periocular infections. (4.1)
• Advanced glaucoma. (4.2)

FULL PRESCRIBING INFORMATION:
Revised: June 2009

INDICATIONS AND USAGE
OZURDEX™ (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). (1)

2.1 General Dosing Information
For ophthalmic intravitreal injection only.

ADVERSE REACTIONS
The most common adverse reactions reported by ≥20% of patients included increased intraocular pressure and conjunctival hemorrhage. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or www.allergan.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

These highlights do not include all the information needed to use OZURDEX™ safely and effectively. See full prescribing information.

OZURDEX™ (dexamethasone intravitreal implant)
Initial U.S. Approval: 1958

CONTRAINDICATIONS
• Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1)
• Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex. (5.2)

WARNINGS AND PRECAUTIONS
• Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (5.1)

2.2 Administration
The intravitreal injection procedure should be carried out under controlled aseptic conditions which include the use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide are recommended to be given prior to the injection. Remove the foil pouch from the carton and examine for damage. Then, in a sterile field, open the foil pouch and gently place the applicator on a sterile tray. Carefully remove the cap from the applicator. Hold the applicator in one hand and pull the safety tab straight off the applicator. Do not twist or flex the tab. The long axis of the applicator should be held parallel to the limbus, and the sclera should be engaged at an oblique angle with the bevel of the needle up (away from the sclera) to create a shielded scleral path. The tip of the needle is advanced within the sclera for about 1 mm (parallel to the limbus) then re-directed toward the center of the eye and advanced until penetration of the sclera is completed and the vitreous cavity is entered. The needle should not be advanced past the point where the sleeve touches the conjunctiva.

Slowly depress the actuator button until an audible click is noted. Before withdrawing the applicator from the eye, make sure that the actuator button is fully depressed and has locked flush with the applicator surface. Remove the needle in the same direction as used to enter the vitreous.

Following the intravitreal injection, patients should be monitored for elevation in intraocular pressure and for endophthalmitis. Monitoring may consist of a check for perfusion of the optic nerve head immediately after the injection, tonometry within 30 minutes following the injection, and biomicroscopy between two and seven days following the injection. Patients should be instructed to report any symptoms suggestive of endophthalmitis without delay.

Each applicator can only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new applicator must be used, and the sterile field, syringe, gloves, drapes, and eyelid speculum should be changed before OZURDEX™ is administered to the other eye.

3. DOSAGE FORMS AND STRENGTHS
Intravitreal implant containing dexamethasone 0.7 mg in the NOVADUR™ solid polymer drug delivery system.

4. CONTRAINDICATIONS
• Ocular or Periocular Infections
OZURDEX™ (dexamethasone intravitreal implant) is contraindicated in patients with active or suspected ocular or periocular infections including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. (4.1)

• Advanced Glaucoma
OZURDEX™ is contraindicated in patients with advanced glaucoma. (4.2)

• Hypersensitivity
OZURDEX™ is contraindicated in patients with known hypersensitivity to any components of this product. (4.3)

5. WARNINGS AND PRECAUTIONS
5.1 Intravitreal Injection-related Effects
Intravitreal injections have been associated with endophthalmitis, eye inflammation, increased intraocular pressure, and retinal detachments. Patients should be monitored following the injection. (see PATIENT COUNSELING INFORMATION, 17)

5.2 Potential Steroid-related Effects
Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. Corticosteroids should be used cautiously in patients with a history of ocular herpes simplex. Corticosteroids should not be used in active ocular herpes simplex.

6. ADVERSE REACTIONS
6.1 Clinical Studies Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The following information is based on the combined clinical trial results from the initial 6 month masked period of two randomized, sham-controlled, parallel studies.

8. ADVERSE REACTIONS
8.1 Transient Elevation in Intraocular Pressure
Elevation in intraocular pressure and conjunctival hemorrhage. (6.1)

8.2 Clinical Ocular Effects
Use of corticosteroids may produce posterior subcapsular cataracts, increased intraocular pressure, glaucoma, and may enhance the establishment of secondary ocular infections due to bacteria, fungi, or viruses. (6.1)

8.3 Nursing Mothers
Nursing Mothers (8.4)

8.4 Pediatric Use
Pediatric Use (8.5)

8.5 Geriatric Use
Geriatric Use (8.6)

11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION
1 INDICATIONS AND USAGE
OZURDEX™ (dexamethasone intravitreal implant) is indicated for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).

2 DOSAGE AND ADMINISTRATION
2.1 General Dosing Information
For ophthalmic intravitreal injection only.

www.fda.gov/medwatch.
Bione, 9-fluoro-11,17,21-trihydroxy-16-methyl-,(11

OZURDEX™ is preservative-free. The chemical name for dexamethasone is pregna-1,4-diene-3,20-

The PLGA matrix slowly degrades to lactic acid and glycolic acid.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Dexamethasone, a potent corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage and migration of inflammatory cells.

12.3 Pharmacokinetics

Plasma concentrations were obtained from 21 patients in the two, 6-month Phase 3 efficacy studies prior to dosing and on Days 7, 30, 60, and 90 following the intravitreal implant containing 0.35 mg or 0.7 mg dexamethasone. In both studies, the majority of plasma dexamethasone concentrations were below the lower limit of quantitation (LLLOQ= 39 pg/mL). Plasma dexamethasone concentrations from 10 of 73 samples in the 0.7 mg dose group and from 2 of 42 samples in the 0.35 mg dose group were above the LLLOQ, ranging from 52 pg/mL to 94 pg/mL. The highest plasma concentration value of 94 pg/mL was observed in one subject from the 0.7 mg group. Plasma dexamethasone concentration did not appear to be related to age, body weight, or sex of patients.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

No adequate studies in animals have been conducted to determine whether OZURDEX™ (dexamethasone intravitreal implant) has the potential for carcinogenesis. Although no adequate studies have been conducted to determine the mutagenic potential of OZURDEX™, dexamethasone has been shown to have no mutagenic effects in bacterial and mammalian cells in vitro or in the in vivo mouse micronucleus test.

14 CLINICAL STUDIES

The efficacy of OZURDEX™ was assessed in two, multicenter, double-masked, randomized, parallel studies. Following a single injection, OZURDEX™ for the treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) demonstrated the following clinical results for the percent of patients with ≥15 letters of improvement from baseline in best-corrected visual acuity (BCVA):

<table>
<thead>
<tr>
<th>Number (Percent) of Patients with ≥15 Letters Improvement from Baseline in BCVA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study 1 Study 2</td>
</tr>
<tr>
<td>Sham Sham</td>
</tr>
<tr>
<td>Sham Sham</td>
</tr>
<tr>
<td>DEX 700 n=201 p-value DEX 700 n=202 p-value</td>
</tr>
<tr>
<td>Study Day</td>
</tr>
<tr>
<td>Day 30</td>
</tr>
<tr>
<td>Day 60</td>
</tr>
<tr>
<td>Day 90</td>
</tr>
<tr>
<td>Day 180</td>
</tr>
</tbody>
</table>

* P-values were based on the Pearson’s Chi-square test.

In each individual study and in a pooled analysis, time to achieve ≥ 15 letters (3-line) improvement in BCVA cumulative response rate curves were significantly faster with OZURDEX™ compared to sham (p < 0.01), with OZURDEX™-treated patients achieving a 3-line improvement in BCVA earlier than sham-treated patients.

The onset of a ≥15 letter (3 line) improvement in BCVA with OZURDEX™ occurs within the first two months after implantation in approximately 25-30% of subjects. The duration of effect persists approximately one to three months after onset of this effect.

16 HOW SUPPLIED/STORAGE AND HANDLING

OZURDEX™ (dexamethasone intravitreal implant) 0.7 mg is supplied in a foil pouch with 1 single-use plastic applicator, NDC 0023-3348-07.

Storage: Store at 15° - 30° C (59° - 86° F).

Patients may experience temporary visual blurring after receiving an intravitreal injection. They should not drive or use machines until this has resolved.

© 2009 Allergan, Inc.

 Irvine, CA 92612, U.S.A.

© and ™ marks owned by Allergan, Inc.

Made in Ireland